Garcinia kola aqueous suspension prevents cerebellar neurodegeneration in long-term diabetic rat - a type 1 diabetes mellitus model

J Ethnopharmacol. 2017 Jan 4:195:159-165. doi: 10.1016/j.jep.2016.11.001. Epub 2016 Nov 5.

Abstract

Ethnopharmacological relevance: The development of compounds able to improve metabolic syndrome and mitigate complications caused by inappropriate glycemic control in type 1 diabetes mellitus is challenging. The medicinal plant with established hypoglycemic properties Garcinia kola Heckel might have the potential to mitigate diabetes mellitus metabolic syndrome and complications.

Aim of the study: We have investigated the neuroprotective properties of a suspension of G. kola seeds in long-term type 1 diabetes mellitus rat model.

Materials and methods: Wistar rats, made diabetic by single injection of streptozotocin were monitored for 8 months. Then, they were administered with distilled water or G. kola oral aqueous suspension daily for 30 days. Body weight and glycemia were determined before and after treatment. After sacrifice, cerebella were dissected out and processed for stereological quantification of Purkinje cells. Histopathological and immunohistochemical analyses of markers of neuroinflammation and neurodegeneration were performed.

Results: Purkinje cell counts were significantly increased, and histopathological signs of apoptosis and neuroinflammation decreased, in diabetic animals treated with G. kola compared to diabetic rats given distilled water. Glycemia was also markedly improved and body weight restored to non-diabetic control values, following G. kola treatment.

Conclusions: These results suggest that G. kola treatment improved the general condition of long-term diabetic rats and protected Purkinje cells partly by improving the systemic glycemia and mitigating neuroinflammation.

Keywords: Ataxia; D-Glucose (PubChem CID: 5793); Garcinia kola; Medicinal plant; Neuroprotection; Purkinje cell; Streptozotocin (PubChem CID: 29327); Type 1 diabetes mellitus.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Cerebellar Diseases / blood
  • Cerebellar Diseases / etiology
  • Cerebellar Diseases / pathology
  • Cerebellar Diseases / prevention & control*
  • Cerebellum / drug effects*
  • Cerebellum / metabolism
  • Cerebellum / pathology
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / chemically induced
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetic Neuropathies / blood
  • Diabetic Neuropathies / etiology
  • Diabetic Neuropathies / pathology
  • Diabetic Neuropathies / prevention & control*
  • Garcinia kola / chemistry*
  • Hypoglycemic Agents / isolation & purification
  • Hypoglycemic Agents / pharmacology*
  • Nerve Degeneration*
  • Neuroimmunomodulation / drug effects
  • Neuroprotective Agents / isolation & purification
  • Neuroprotective Agents / pharmacology*
  • Phytotherapy
  • Plant Preparations / isolation & purification
  • Plant Preparations / pharmacology*
  • Plants, Medicinal
  • Purkinje Cells / drug effects
  • Purkinje Cells / metabolism
  • Purkinje Cells / pathology
  • Rats, Wistar
  • Streptozocin
  • Time Factors
  • Tumor Necrosis Factor-alpha / metabolism
  • fas Receptor / metabolism

Substances

  • Blood Glucose
  • Fas protein, rat
  • Hypoglycemic Agents
  • Neuroprotective Agents
  • Plant Preparations
  • Tumor Necrosis Factor-alpha
  • fas Receptor
  • Streptozocin